JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB267111

Human C19orf66 knockout A549 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

SHFL KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 3 and 2 bp insertion in exon 3. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Sanger Sequencing - Human C19orf66 knockout A549 cell line (AB267111)
  • Sanger seq

Unknown

Sanger Sequencing - Human C19orf66 knockout A549 cell line (AB267111)

Allele-1 : 1 bp insertion in exon3

Sanger Sequencing - Human C19orf66 knockout A549 cell line (AB267111)
  • Sanger seq

Unknown

Sanger Sequencing - Human C19orf66 knockout A549 cell line (AB267111)

Allele-2 : 2 bp insertion in exon 3.

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 3 and 2 bp insertion in exon 3

Disease

Carcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab267111-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255450 Human wild-type A549 cell line", "number":"AB267111-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab267111 Human C19orf66 knockout A549 cell line", "number":"AB267111-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab267111-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267111 Human C19orf66 knockout A549 cell line", "number":"AB267111-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255450 Human wild-type A549 cell line", "number":"AB267111-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267111-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267111 Human C19orf66 knockout A549 cell line", "number":"AB267111-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267111-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267111 Human C19orf66 knockout A549 cell line", "number":"AB267111-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
SHFL
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
  • Do not allow the cell density to exceed 7x104 cells/cm2.
Culture medium

F-12K + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

C19orf66 also known as Shiftless or C6orf166 is a protein with a molecular mass of approximately 27 kDa. It functions as an inhibitor of viral RNA replication. Research shows that C19orf66 disrupts viral protein synthesis by interacting with viral factors and initiating their degradation making it important for antiviral defense. This protein is expressed in various tissues with high levels detected in immune-related cells suggesting its role in innate immune response.
Biological function summary

C19orf66 plays an essential role in modulating immune response against viral pathogens. Its action involves the inhibition of viral replication which helps in controlling the spread of the infection within the host. C19orf66 does not typically form part of large protein complexes but it exerts its effect through direct interaction with viral components preventing their proper assembly and function.

Pathways

C19orf66 is involved in important antiviral defense mechanisms including those that overlap with the interferon signaling pathway. This protein interacts with interferon-stimulated genes enhancing the host's capability to limit viral infections. Although not directly part of an extensive pathway like NF-kB or MAPK C19orf66 contributes to antiviral defense through its relationship with proteins that are engaged by these pathways during immune responses.

C19orf66 shows implications in viral infections and may play a role in diseases where the immune response is compromised such as chronic viral infections. It has a functional connection with viral proteins which aids in limiting the replication and persistence of viruses. Studies explore its potential usefulness as a therapeutic target especially considering its ability to inhibit the replication of various viruses without directly impacting host cellular machinery.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com